Skip to main content

Table 1 Demographic and clinical characteristics of patients at inclusion visit

From: Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil

 

eGFR ≤ 90* n = 162

eGFR > 90* n = 230

Total* n = 392

P

Age groups (in years)

 18–27

36 (22.2)

119 (51.7)

155 (39.5)

< 0.001

 28–37

80 (49.4)

89 (38.7)

169 (43.1)

 38–47

26 (16.0)

18 (7.8)

44 (11.2)

 48–57

19 (11.7)

4 (1.7)

23 (5.9)

 > 57

1 (0.6)

0 (0.0)

1 (0.3)

Ethnic background

 Caucasian

99 (61.1)

128 (55.7)

227 (57.9)

0.77

 Afro-descendant

17 (10.5)

27 (11.7)

44 (11.2)

 Mixed race

45 (27.0)

72 (31.3)

117 (29.8)

 Indigenous

0 (0.0)

1 (0.4)

1 (0.3)

 Asian

1 (0.6%)

2 (0.9)

3 (0.9)

BMI1 category (kg/m2)

 Underweighta

3 (1.9)

7 (3.0)

10 (2.6)

0.59

 Normalb

69 (42.6)

117 (50.9)

186 (47.4)

 Overweightc

68 (42.0)

77 (33.5)

145 (37.0)

 Obesity class 1d

16 (9.9)

21 (9.1)

37 (9.4)

 Obesity class 2e

3 (1.9)

4 (1.7)

7 (1.8)

 Obesity class 3f

0 (0.0)

1 (0.4)

1 (0.3)

Not measured

3 (1.8)

3 (1.3)

6 (1.5)

Blood pressure (BP) category

 Normalg

101 (62.3)

131 (57)

232 (59.2)

0.64

 High normalh

44 (27.2)

75 (32.6)

119 (30.4)

 Hypertension stage 1i

13 (8.0)

20 (8.7)

33 (8.4)

 Hypertension stage 2j

4 (2.5)

4 (1.7)

8 (2.0)

Semi-quantitative proteinuria

 Absent

120 (74.1)

172 (74.8)

292 (74.5)

0.85

 30–100 mg/dL

12 (7.4)

14 (5.7)

26 (6.4)

 100–300 mg/dL

2 (1.2)

4 (1.7)

6 (1.5)

 300–1000 mg/dL

1 (0.6)

1 (0.4)

2 (0.5)

 > 1000 mg/dL

0 (0.0)

1 (0.4)

1 (0.3)

 Not measured

27 (16.7)

39 (17.0)

66 (16.8)

 
  1. *Data are presented as number of patients (n) followed by percentage in parenthesis (%) 1BMI: body mass index; 2eGFR: estimated glomerular filtration rate; aBMI < 18.5; bBMI 18.5–24.9; cBMI 25.0–29.9; dBMI 30.0–34.9; eBMI 35.0–39.9; fBMI ≥ 40; gBP < 130/85; hBP 130–139/85–89; iBP 140–159/90–99; jBP ≥ 160/ ≥ 100